Liver-on-Chip pioneer CN Bio launches new toxicity testing
Cambridge Science Park 3D cell culture business CN Bio has enhanced its reputation for innovation with the commercial launch of new drug metabolism and safety toxicity testing services.
The new services will incorporate the company’s advanced Liver-on-Chip technology and expertise in the field to enable researchers to generate predictive and human-relevant data – improving the translatability from discovery to clinic and accelerating new drugs to market.
The UK trailblazer is renowned doe having developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery.
Liver toxicity is a principal safety concern during drug discovery and development with the potential to terminate expensive clinical trials already underway.
Based on the success of CN Bio’s Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Fee-For-Service offerings, the new toxicity testing services also provide researchers with additional support and bandwidth during the COVID-19 pandemic when laboratories are not at full capacity.
Similarly to the NAFLD/NASH Fee-For-Service, all studies use the company’s PhysioMimix™ Organ-on-Chip system and in vitro 3D Liver-on-Chip model. This novel approach replicates the physiological and mechanical microenvironment of the liver to fast-track lead targets and generate actionable data in weeks that is reproducible, and cost-effective versus animal studies.
CN Bio’s extended portfolio of services offers solutions to many existing workflow challenges. These include drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with cell health – even for low clearance compounds – and safety toxicity testing.
This latter provides in-depth analysis of acute or chronic drug-induced liver injury using a wide range of endpoints to determine causality and mechanism of toxicity.
The company also provides complimentary service capabilities to support industry and biotechnology organisations that have been impacted by the COVID-19 pandemic.
CEO Dr David Hughes said: “One in 10 drugs successfully reach clinical trials, with safety concerns being the principal cause for subsequent failure.
Through our enhanced drug metabolism and safety toxicity testing services, we enable scientists to take a step beyond what is currently possible with 2D cell culture and animal studies to improve their chances of clinical success.
“Our technologies are on the cutting-edge of research to simulate human biological conditions, in vitro, and we are confident in our ability to support customers in developing tomorrow’s medicines, especially at this challenging time.”